Low-dose rapamycin (Sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized controlled pilot study

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 5, 2014, Pages 881-888

  Braun, William E ^a   Schold, Jesse D ^a   Stephany, Brian R ^a   Spirko, Rita A ^a   Herts, Brian R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DERMATITIS; DISEASE ASSOCIATION; DISEASE COURSE; EDEMA; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BLOOD FLOW; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; MOUTH ULCER; OPEN STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTERIAL PRESSURE; BLOOD; DRUG EFFECTS; FEMALE; KIDNEY; MALE; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RADIOGRAPHY; YOUNG ADULT;

ADULT; AGED; ARTERIAL PRESSURE; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; ORGAN SIZE; PILOT PROJECTS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84906966672     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02650313     Document Type: Article

References (49)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287–1301, 2007
2. King BF, Reed JE, Bergstralh EJ, Sheedy PF 2nd, Torres VE: Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11: 1505–1511, 2000
3. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122–2130, 2006
4. Bae KT, Grantham JJ: Imaging for the prognosis of autosomal dominant polycystickidney disease. Nat Rev Nephrol 6: 96–106, 2010
5. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479–486, 2012
6. Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y: Family historyof renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 20: 1833–1838, 2009
7. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP; CRISP Consortium: Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17: 3013–3019, 2006
8. Qian F, Watnick TJ, Onuchic LF, Germino GG: The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87: 979–987, 1996
9. Takakura A, Contrino L, Zhou X, Bonventre JV, Sun Y, Humphreys BD, Zhou J: Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum Mol Genet 18: 2523–2531, 2009
10. Grantham JJ, Mulamalla S, Grantham CJ, Wallace DP, Cook LT, Wetzel LH, Fields TA, Bae KT: Detected renal cysts are tips of the iceberg in adults with ADPKD. Clin J Am Soc Nephrol 7: 1087–1093, 2012
11. Belibi FA, Edelstein CL: Novel targets for the treatment of auto-somal dominant polycystic kidney disease. Expert Opin Investig Drugs 19: 315–328, 2010
12. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: The last 3 years. Kidney Int 76: 149–168, 2009
13. Lieberthal W, Levine JS: Mammalian target of rapamycin and the kidney. I. The signaling pathway. Am J Physiol Renal Physiol 303: F1–F10, 2012
14. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159–168, 2006
15. Lieberthal W, Levine JS: Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. Am J Physiol Renal Physiol 303: F180–F191, 2012
16. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt K-U: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830–840, 2010
17. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP: Sirolimus and kidney growth in autosomal domi-nantpolycystic kidney disease. N Engl JMed 363: 820–829, 2010
18. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21: 1031–1040, 2010
19. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46–51, 2005
20. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598–604, 2006
21. Zhang T, Wang L, Xiong X, Mao Z, Wang L, Mei C: Mycophe-nolate mofetil versus rapamycin in Han:SPRD rats with poly-cystic kidney disease. Biol Res 42: 437–444, 2009
22. Zafar I, Belibi FA, He Z, Edelstein CL: Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349–2353, 2009
23. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466–5471, 2006
24. Shillingford JM, Piontek KB, Germino GG, Weimbs T: Rapamy-cin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21: 489–497, 2010
25. Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ: Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 23: 842–853, 2012
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
27. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW: The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol 5: 102–109, 2010
28. Rolin HA, Hall PM: Evaluation of glomerular filtration rate and renal plasma flow. In: The Principles and Practice of Nephrology, edited by Klahr S, Jacobson HR, Striker GE, Philadelphia: Dekker, 1989, p 158
29. Wang S, Miller A: A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. Clin Chem Lab Med 46: 1631–1634, 2008
30. Kamel IR, Kruskal JB, Warmbrand GS, Goldberg SN, Pomfret EA, Raptopoulos V: Accuracy of volumetric measurements after virtual right hepatectomy in potential donors undergoing living adult liver transplantation. AJR Am J Roentgenol 176: 483–487, 2001
31. Johnson AM, Gabow PA: Identification of patients with autoso-mal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8: 1560–1567, 1997
32. Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ, Somlo S, Cantley LG: Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22: 1809–1814, 2011
33. Carvalhosa R, Deambrosis I, Carrera P, Pasquino C, Rigo F, Ferrari M, Lasaponara F, Ranghino A, Biancone L, Segoloni G, Bussolati B, Camussi G: Cystogenic potentialofCD133+ progenitor cells of human polycystic kidneys. J Pathol 225: 129–141, 2011
34. Comalada M, Valledor AF, Sanchez-Tilló E, Umbert I, Xaus J, Celada A: Macrophage colony-stimulating factor-dependent macrophage proliferation is mediated through a calcineurin-independent but immunophilin-dependent mechanism that mediates the activation of external regulated kinases. Eur J Immunol 33: 3091–3100, 2003
35. Fox R, Nhan TQ, Law GL, Morris DR, Liles WC, Schwartz SM: PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. EMBO J 26: 505–515, 2007
36. Caroli A, Antiga L, Conti S, Sonzogni A, Fasolini G, Ondei P, Perico N, Remuzzi G, Remuzzi A: Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. Am J Pathol 179: 619–627, 2011
37. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP; CRISP Consortium: Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: The consortium of radiologic imaging studies of polycystic kidney disease cohort. JAmSoc Nephrol 17: 854–862, 2006
38. Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaime´ F, Thervet E, Martinez F, Terzi F, Legendre C: Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant 10: 1701–1706, 2010
39. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP: The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 18: 151–163, 2009
40. Watnick T, Germino GG: Mtor inhibitors in polycystic kidney disease. [Editorial] N Engl J Med 363: 879–881, 2010
41. Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME; Modification of Diet in Renal Disease Study Group: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 5: 2037–2047, 1995
42. Walz G, Budde K, Eckardt K-U: Mtor inhibitor and autosomal dominant polycystic kidney disease. N Engl J Med 364: 287–288, 2011
43. O’Sullivan DA, Torres VE, Heit JA, Liggett S, King BF: Compression of the inferior vena cava by right renal cysts: An unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystickidney disease. Clin Nephrol Letters to the editor 49: 332-334, 1998
44. Tveit DP, Hypolite I, Bucci J, Hshieh P, Cruess D, Agodoa LYC, Welch PG, Abbott KC: Risk factors for hospitalizations resulting from pulmonary embolism after renal transplantation in the United States. J Nephrol 14: 361–368, 2001
45. Wyeth Pharmaceutical Data on File Nov 9, 2007
46. Langer RM, Kahan BD: Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients. Transplantation 76: 318–323, 2003
47. Hiura T, Yamazaki H, Saeki T, Kawabe S, Ueno M, Nishi S, MiyamuraS,GejyoF:Nephrotic syndromeandIgAnephropathyin polycystic kidney disease. Clin Exp Nephrol 10: 136–139, 2006
48. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A: A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1: 109–116, 2006
49. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi M-N, Helal I, Noël L-H, Legendre C: Highsirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326–333, 2007